Preclinical pharmacology

Where the data comes from

Pharmacokinetics in mice

• Orally bioavailable
• Brain-to-plasma ratio approximately 3:1
• Half-life approximately 6–8 hours
• Suitable for oral b.i.d. dosing in chronic studies[3]

These properties — long half-life, good brain penetration, good oral bioavailability — are why SR-17018 is the only feasible route by mouth in humans, and why the compound's effects are reported to last 6–12 hours per dose.

Pain relief

SR-17018 is active in multiple mouse pain models, and in rhesus monkeys at the spinal level.

• Active in hot plate, tail flick, formalin (inflammatory), and paclitaxel-induced neuropathic pain models in mice
• In chemotherapy-induced neuropathic pain, SR-17018 was reported as more potent and efficacious than morphine or oxycodone, with retained efficacy on chronic dosing[3]
• In rhesus monkeys, intrathecal SR-17018 (30–300 μg) attenuated capsaicin-induced thermal allodynia; effects were reversible by naltrexone[7]

Tolerance

• Hot plate test: No or minimal tolerance with chronic SR-17018 dosing[2]
• Formalin and paclitaxel-induced pain: Efficacy retained with chronic dosing
• Tail flick test: Tolerance does develop, similar to morphine and oxycodone — a clear exception to the "no tolerance" narrative
• Tolerance reversal: Substitution with SR-17018 in morphine-tolerant mice restored morphine potency on hot plate[2]

Respiratory depression — the nuance

• In the original 2017 work, intraperitoneal SR-17018 in mice produced robust analgesia with very little respiratory depression. The estimated therapeutic window (respiratory depression / analgesia ratio) was 26–105 for SR-17018, compared to 5–21 for morphine and 2–5 for fentanyl[1].
• Subsequent work using oral administration — which has higher and more sustained bioavailability than IP, and is the only route used in humans — found that SR-17018 does produce significant respiratory depression in mice.
• The Fritzwanker 2021 phosphorylation work[4] and Stahl 2021 noncompetitive-binding work[5] both suggest that at higher exposures the apparent bias breaks down, which is consistent with the oral respiratory finding.

The accurate summary: SR-17018 has a wider therapeutic window than fentanyl or morphine in mouse parenteral assays, but it is not free of respiratory depression, and its safety advantage is dose- and route-dependent.

Dependence and withdrawal

• Substitution of SR-17018 in morphine-dependent mice prevents the onset of morphine withdrawal[2].
• SR-17018 itself produces dependence in mice. Kudla et al. (2022) demonstrated rewarding effects in conditioned place preference and a clear withdrawal syndrome on discontinuation[6]. The compound is not free of dependence liability.

Reinforcing strength / abuse liability

In rhesus monkey IV self-administration under a progressive-ratio schedule, SR-17018 (3–30 μg/kg/infusion) had lower reinforcing strength than heroin and was comparable to buprenorphine[7]. This is consistent with its low intrinsic efficacy at MOR.

Naloxone reversibility

Despite non-competitive binding kinetics, SR-17018-mediated MOR activation is fully reversible by naloxone in cellular and animal assays. The related compound SR-14968 was also shown to be naloxone-reversible at respiratory-depressant doses[8]. Naloxone is therefore the appropriate response to suspected SR-17018 overdose, the same as for any other opioid.